AstraZeneca's Calquence receives FDA Priority Review for previously untreated mantle cell lymphoma, showing promising Phase 3 trial results in reducing disease progression by 27%. An FDA decision is anticipated in Q1 2025. read more
AstraZeneca Seeks Expanded Use For Blood Cancer Drug Calquence, FDA Grants Priority Review